Tag: Silk Road Medical
Boston Scientific closes acquisition of Silk Road Medical
Boston Scientific has announced the close of its acquisition of Silk Road Medical—a medical device company that has pioneered a new approach for stroke prevention and...
Silk Road celebrates milestone of 100,000 TCAR procedures
Silk Road Medical has announced the milestone of more than 100,000 transcarotid artery revascularisation (TCAR) procedures having been performed to date.
“A growing number of...
Boston Scientific announces agreement to acquire Silk Road Medical
Boston Scientific has announced that it has entered into a definitive agreement to acquire Silk Road Medical, a medical device company involved in producing...
Silk Road adds Enroute NPS Plus device to TCAR portfolio
Silk Road Medical has announced the launch of its Enroute transcarotid neuroprotection system Plus (NPS Plus), which the company describes as a key component of...
Silk Road expands TCAR portfolio with launch of tapered Enroute system
Silk Road Medical has announced the launch of its tapered Enroute transcarotid stent system to hospitals in the USA, expanding upon the company’s prior...
Silk Road Medical announces first patient enrolled in ROADSTER 3 post-approval...
Silk Road Medical has announced enrolment of the first patient in ROADSTER 3, which the company claims is the the first prospective, multicentre, single-arm...
Silk Road to evaluate TCAR in standard surgical risk patients with...
Silk Road Medical today announced a post-market study to evaluate the transcarotid artery revascularisation (TCAR) system in the treatment of standard surgical risk patients...
Silk Road Medical announces expanded Medicare coverage for TCAR in standard...
Silk Road Medical recently announced that the Centers for Medicare and Medicaid Services (CMS), through collaboration with the Society of Vascular Surgery’s Patient Safety...
Silk Road Medical announces FDA approval of expanded indications for the...
Silk Road Medical recently announced that the US Food and Drug Administration (FDA) approved expanded indications for the company's Enroute stent to include patients...
Cost-effectiveness of TCAR versus carotid endarterectomy addressed in new study
A cost-effectiveness model based on peer-reviewed sources suggests that, although five-year costs for transcarotid artery revascularisation (TCAR; Silk Road Medical) were higher than those for...
TCAR may be associated with favourable outcomes for treatment of restenotic...
Transcarotid artery revascularisation (TCAR; Silk Road Medical) may be associated with favourable in-hospital outcomes for the treatment of restenotic carotid lesions after carotid endarterectomy...
First ever analysis of TCAR in standard surgical risk patients demonstrates...
Silk Road Medical has announced positive results from an independent analysis of standard surgical risk patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularisation...
Study finds hospital availability of TCAR associated with an improvement in...
Silk Road Medical has announced positive results from a comparative-effectiveness study have been published in JAMA Network Open.
The study found the availability of TCAR...
